David Michael Clark - 11 Jan 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 Jan 2023, 16:12:40 UTC
Prior SEC filing
06 Jan 2023
Next SEC filing
19 Jan 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christian Formica, Attorney-in-Fact

Key filing fact

David Michael Clark filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 13 Jan 2023.

Key facts

  • This page summarizes David Michael Clark's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 13 Jan 2023, 16:12.

Change

  • Previous filing in this sequence was filed on 06 Jan 2023.
  • Current net transaction value: -$225,231.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FOLD transaction

Common Stock

Award

Transaction value
$0
Shares
+47,621
Change %
+22%
Price
$0.000000
Shares after
267,187
Date
11 Jan 2023
Ownership
Direct
Footnotes
F1
FOLD transaction

Common Stock

Tax liability

Transaction value
$225,231
Shares
-18,738
Change %
-7%
Price
$12.02
Shares after
248,449
Date
11 Jan 2023
Ownership
Direct
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted for the achievement of the 2020 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .